Biotechnology - Biotechnology, Immunologicals

Filter

Popular Filters

1 to 25 of 70 results

Intas becomes first Indian company to launch biosimilar in the EU

Intas becomes first Indian company to launch biosimilar in the EU

23-02-2015

Indian biopharma company Intas has become the first Indian company to launch a biosimilar in highly regulated…

BiosimilarsBiotechnologyFilgrastimHematologyImmunologicalsIndiaIntas PharmaceuticalsMarkets & MarketingRegulation

Genmab inks DuoBody deal with BioNovion in the field of immuno-oncology

19-02-2015

Danish biotech company Genmab has entered into a co-development and commercialization agreement with…

BioNovionBiotechnologyDuoBodyGenmabImmunologicalsLicensingOncologyResearch

Seth Elliott appointed president and chief operating officer of Immune Therapeutics

14-01-2015

Immunotherapy specialist Immune Therapeutics has appointed Seth Elliott as president and chief operating…

BiotechnologyBoardroomImmune TherapeuticsImmunologicalsUSA

FDA staffers back approval of Novartis' biosimilar of Amgen's Neupogen

FDA staffers back approval of Novartis' biosimilar of Amgen's Neupogen

06-01-2015

In briefing papers ahead of an advisory committee meeting, agency staff at the US Food and Drug Administration…

AmgenBiosimilarsBiotechnologyImmunologicalsNeupogenNovartisRegulationUSA

EpiVax links with Novozymes Biopharma to advance autoimmune diseases treatment

23-12-2014

Danish drugmaker Novozymes’ Veltis albumin-based half-life extension platform will help move Tregitope…

BiotechnologyImmunologicalsLicensingNovozymesResearchTregitopeVeltis

Tiziana licenses anti-inflammatory foralumab from Novimmune

Tiziana licenses anti-inflammatory foralumab from Novimmune

22-12-2014

Oncology and immunology specialist Tiziana and antibody-based drug manufacturer Novimmune have entered…

BiotechnologyImmunologicalsLicensingNovImmuneTiziana

PDS Biotechnology appoints Richard Sykes executive chairman of its board of directors

PDS Biotechnology appoints Richard Sykes executive chairman of its board of directors

18-12-2014

Immunotherapeutic company PDS Biotechnology has made Richard Sykes executive chairman of its board of…

BiotechnologyBoardroomImmunologicalsPDS BiotechnologyUK

Neovacs' Phase IIb study of TNF-Kinoid in rheumatoid arthritis fails to meet primary endpoints

Neovacs' Phase IIb study of TNF-Kinoid in rheumatoid arthritis fails to meet primary endpoints

16-12-2014

French autoimmune specialist Neovacs says that its Phase IIb trial of TNF-Kinoid in rheumatoid arthritis…

BiotechnologyFranceImmunologicalsNeovacsResearchTNF-Kinoid

Stallergenes exercises option to develop allergy treatments with ActoGeniX

Stallergenes exercises option to develop allergy treatments with ActoGeniX

21-11-2014

Global allergenics company Stallergenes is to exercise the option to pursue the exclusive development…

ActoGeniXBiotechnologyImmunologicalsProductionResearchStallergenes

Xencor regains rights to XmAb5871 from Amgen

29-10-2014

US drug developer Xencor revealed yesterday that it has regained all development and commercial rights…

AmgenAnti-Arthritics/RheumaticsBiotechnologyImmunologicalsLicensingResearchXencorXmAb5871

Prima BioMed to acquire Immutep for $28 million

Prima BioMed to acquire Immutep for $28 million

03-10-2014

France-based Immutep, a late-stage private biopharmaceutical company in the rapidly growing field of…

BiotechnologyFranceImmunologicalsImmutepMergers & AcquisitionsOncologyPrima BioMed

Sigma-Aldrich acquires Cell Marque to grow antibody portfolio

Sigma-Aldrich acquires Cell Marque to grow antibody portfolio

03-10-2014

USA-based life sciences company Sigma-Aldrich has entered into an agreement to acquire US antibody company…

AnatomyBiologyBiotechnologyImmunologicalsMergers & AcquisitionsProtein methodsSigma-AldrichUSA

Denmark’s Forward Pharma plans IPO

Denmark’s Forward Pharma plans IPO

02-10-2014

Denmark-based Forward Pharma A/S today announced it has commenced an underwritten initial public offering…

BiotechnologyDenmarkFinancialForward PharmaImmunologicals

FDA approves Baxter/Halozyme’s HyQvia

FDA approves Baxter/Halozyme’s HyQvia

14-09-2014

The US Food and Drug Administration on Friday approved Baxter International’s and Halozyme Therapeutics’…

Baxter InternationalBiotechnologyHalozyme TherapeuticsHyQviaImmunologicalsRegulationUSA

Payers exert cost controls on high-cost biologics to treat autoimmune conditions

Payers exert cost controls on high-cost biologics to treat autoimmune conditions

21-08-2014

Surveyed managed care organizations (MCOs) anticipate that their costs of covering biologic treatments…

Anti-Arthritics/RheumaticsBiotechnologyFinancialHealthcareImmunologicals

New drugs to boost graft-versus-host disease treatment market by 2018

New drugs to boost graft-versus-host disease treatment market by 2018

15-08-2014

The graft-versus-host disease (GVHD) treatment market value will increase from $297 million in 2013 to…

Adienne PharmaBegedinaBiotechnologyBudenofalkDr Falk PharmaEuropeImmunologicalsJazz PharmaceuticalsMarkets & MarketingMesoblastProchymalUSA

FDA advisory panel backs Baxter’s HyQvia for primary immunodeficiency

FDA advisory panel backs Baxter’s HyQvia for primary immunodeficiency

01-08-2014

The Blood Products Advisory Committee of the US Food and Drug Administration has voted 15-1 that HyQvia…

Baxter InternationalBiotechnologyHalozyme TherapeuticsHyQviaImmunologicalsRegulationUS Food and Drug AdministrationUSA

Global regenerative medicine market expected to reach $67 billion by 2020

Global regenerative medicine market expected to reach $67 billion by 2020

15-07-2014

The global regenerative medicine market will reach $67.6 billion by 2020, up from $16.4 billion in 2013…

BiotechnologyGlobalImmunologicalsMarkets & MarketingRegenerative medicineResearchStem cells

Beike receives approval from Chinese FDA for umbilical stem cells in lupus

Beike receives approval from Chinese FDA for umbilical stem cells in lupus

10-07-2014

China-based stem cell research company Beike Biotechnology has been accepted into the approval process…

beikeBeike BiotechnologyBiotechnologyChinaGuangdong Food and Drug AdministrationImmunologicalsRegulationStem cells

MorphoSys and Merck Serono collaborate on immuno-oncology

MorphoSys and Merck Serono collaborate on immuno-oncology

12-06-2014

German companies MorphoSys and Merck KGaA unit Merck Serono today announced the signing of an agreement…

BiotechnologyCancer therapyHealth Medical PharmaHuman antibody technologiesImmune systemImmunologicalsLeaderLicensingMerck KGaAMerck SeronoMorphoSysOncologyResearch

Array BioPharma inks deal with Biogen Idec on autoimmune disorders

Array BioPharma inks deal with Biogen Idec on autoimmune disorders

30-05-2014

US biotech firms Array BioPharma and Biogen Idec have entered into a collaboration for the discovery…

Array BioPharmaBiogen IdecBiotechnologyImmunologicalsLicensingResearch

MacroGenics and Takeda link up to develop DART for autoimmune disorders

27-05-2014

Privately held US biotech firm MacroGenics and Japan’s largest drugmaker Takeda Pharmaceutical have…

BiotechnologyImmunologicalsLicensingMacroGenicsMGD010Takeda Pharmaceutical

Eisai's R&D unit Kan Research Institute starts full-scale operation at new facility

27-05-2014

Japanese drug major Eisai Co says that its R&D subsidiary KAN Research Institute held a dedication ceremony…

BiotechnologyEisaiImmunologicalsJapanKan Research InstituteNeurologicalOncologyResearch

FDA extends PDUFA date for Baxter and Halozyme’s HyQvia

21-05-2014

US drugmakers Baxter International and Halozyme Therapeutics revealed that the US Food and Drug Administration…

Baxter InternationalBiotechnologyHalozyme TherapeuticsHyQviaImmunologicalsRegulationUSA

1 to 25 of 70 results

COMPANY SPOTLIGHT

Menarini

Back to top